Business
Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the
About this update from Dianthus Therapeutics, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nMagenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Thomas Beetham as Chief Legal Officer.\n\n“We welcome Tom’s extensive legal expertise and cross-functional leadership background,” said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. “I look forward to working alongside him as Magenta continues to progress across our preclinical and clinical pipeline.”\n\nAs Chief Legal Officer, Mr. Beetham will serve as a member of the Company’s Executive Team and will be responsible for leading all aspect of Magenta’s legal and compliance operations.\n\nMr. Beetham comes to Magenta with more than 20 years of experience in legal, business development, operations and strategy across the biotechnology and pharmaceutical industries. He joins Magenta most recently from Kiniksa Pharmaceuticals, where he served as Chief Legal Officer and Executive Vice President, Corporate Development and Operations, where he oversaw all company legal matters, including transactions, financings, corporate and securities, public company reporting, tax, international, real estate, human resources and more. Previously, he was Chief Legal Officer at Synageva BioPharma, among other roles of increasing responsibility. Mr. Beetham’s additional experience includes legal leadership roles at New England BioLabs, Inc., Genzyme Corporation, and Palmer & Dodge LLP.\n\nMr. Beetham holds JD and MBA degrees from Boston College and a Bachelor of Arts degree from the University of Rochester.\n\nAbout Magenta Therapeutics\n\nMagenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.\n\nMagenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.\n\nFollow Magenta on Twitter: @magentatx.\n\nForward-Looking Statement\n\nThis pre...